




EMLc

ATC codes: **A04AA01**

Indication	Nausea or vomiting <span style="background-color: #00a651; color: white; padding: 2px;">ICD11 code: MG10</span>
INN	Ondansetron
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride) Oral > Liquid: 4 mg per 5 mL (ondansetron base) Oral > Solid: 4 mg (ondansetron base) ; 8 mg (ondansetron base) ; 24 mg (ondansetron base) (EML)
EML status history	First added in 2009 (TRS 958) Changed in 2019 (TRS 1021) Changed in 2021 (TRS 1035)
Sex	All
Age	Also recommended for children
Age restriction	> 1 month
Therapeutic alternatives	dolasetron (ATC codes: A04AA04) granisetron (ATC codes: A04AA02) palonosetron (ATC codes: A04AA05) tropisetron (ATC codes: A04AA03)
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Ondansetron</a> 
DrugBank	<a href="#">Ondansetron</a> 

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that dolasetron, granisetron, palonosetron and tropisetron be specified as therapeutic alternatives under the square box listing for ondansetron on the EML and EMLc.

